Tag: Hepatitis

Findings seen for those with normal alanine transaminase and especially for patients with HBV DNA ≥2,000 IU/mL

Authors recommend hepatitis C treatment with sofosbuvir-based regimens should be expanded, including to those receiving dialysis

Two-week DAA optimal for preventing infection in individuals without HCV viremia who received kidney from HCV-viremia-positive donors

Higher odds of receiving DAA treatment seen for younger age, being seen by a gastroenterologist or infectious disease physician, having cirrhosis

Four recommendations include HCV testing of all perinatally exposed infants with nucleic acid testing for HCV RNA at age 2 to 6 months

Nearly two-thirds with hepatitis A-related deaths had at least one documented indication for vaccination; only 4 percent vaccinated

Revaccination should be considered for patients with chronic HCV who do not respond to HBV vaccination

Since 2017, leading cause of HCC is NAFLD among women; increases in ALD- and NAFLD-HCC seen since 2015

Guidelines developed for hepatitis B, C virus screening in pregnancy, management of infection, vaccination

All-cause mortality considerably higher across all disease severity groups than for the general population